MedTrace Logo

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

NCT03594045 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-12-23

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT).

The drug involved in this study is apixaban.

Conditions

  • Heparin-induced Thrombocytopenia
  • Heparin-induced Thrombocytopenia and Thrombosis

Interventions

DRUG

Apixaban

Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.

Sponsors & Collaborators

Principal Investigators

  • Rachel P Rosovsky, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2019-10-30
Completion
2019-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03594045 on ClinicalTrials.gov